{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T14:57:41Z","timestamp":1763564261570,"version":"build-2065373602"},"reference-count":38,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T00:00:00Z","timestamp":1678060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Bevacizumab (BEV) is beneficial for ovarian cancer patients, but the real world\u2019s patient settings differ from those in clinical trials. This study tries to illustrate adverse events in the Taiwanese population. Patients with epithelial ovarian cancer treated with BEV at Kaohsiung Chang Gung Memorial Hospital between 2009 and 2019 were retrospectively reviewed. The receiver operating characteristic curve was adopted to identify the cutoff dose and the presence of BEV-related toxicities. A total of 79 patients receiving BEV in neoadjuvant, frontline, or salvage settings were enrolled. The median follow-up time was 36.2 months. Twenty patients (25.3%) had \u201cDe novo\u201d hypertension or the worsening of a preexisting one. Twelve patients (15.2%) had \u201cDe novo\u201d proteinuria. Five patients (6.3%) had thromboembolic events\/hemorrhage. Four patients (5.1%) had gastrointestinal perforation (GIP), and one patient (1.3%) had wound-healing complications. Patients with BEV-related GIP had at least two risk factors for developing GIP, most of which were conservatively managed. This study revealed a compatible but distinct safety profile from those reported in clinical trials. The presence of BEV-related changes in blood pressure showed a dose-dependent trend. Most of the BEV-related toxicities were managed individually. Patients with potential risks for developing BEV-related GIP should use BEV with caution.<\/jats:p>","DOI":"10.3390\/jcm12052065","type":"journal-article","created":{"date-parts":[[2023,3,6]],"date-time":"2023-03-06T04:29:58Z","timestamp":1678076998000},"page":"2065","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Safety Analysis of Bevacizumab in Ovarian Cancer Patients"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1997-5521","authenticated-orcid":false,"given":"Yingwen","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City 833, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0828-6763","authenticated-orcid":false,"given":"Hao","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City 833, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuche","family":"Ou","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Chia-Yi Chang Gung Memorial Hospital, Chiayi County 613, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0660-9349","authenticated-orcid":false,"given":"Hungchun","family":"Fu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City 833, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chingchou","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City 833, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chanchao Chang","family":"Chien","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City 833, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2187-1046","authenticated-orcid":false,"given":"Chenhsuan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City 833, Taiwan"},{"name":"Graduate Institute of Clinical Medical Sciences, Chang Gung University, Taoyuan City 333, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ejca.2018.07.005","article-title":"Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018","volume":"103","author":"Ferlay","year":"2018","journal-title":"Eur. J. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA A Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3322\/caac.21456","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA A Cancer J. Clin."},{"key":"ref_4","unstructured":"Health Promotion Administration, Ministry of Health and Welfare, Taiwan (2023, January 13). Cancer Registry Annual Report 2018 Taiwan, Available online: https:\/\/www.hpa.gov.tw\/Pages\/Detail.aspx?nodeid=269&pid=13498."},{"key":"ref_5","unstructured":"Taiwan Cancer Registry Center (2023, January 13). Cancer Survival Rates in Taiwan. Available online: http:\/\/tcr.cph.ntu.edu.tw\/uploadimages\/Survival_103_107.pdf."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ygyno.2013.03.026","article-title":"An international assessment of ovarian cancer incidence and mortality","volume":"130","author":"Lowe","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_8","first-page":"Cd007565","article-title":"Optimal primary surgical treatment for advanced epithelial ovarian cancer","volume":"2011","author":"Elattar","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"7439","DOI":"10.1158\/1078-0432.CCR-04-0683","article-title":"Recurrent ovarian cancer: How important is it to treat to disease progression?","volume":"10","author":"Herzog","year":"2004","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S1470-2045(11)70123-1","article-title":"Evolution of platinum resistance in high-grade serous ovarian cancer","volume":"12","author":"Cooke","year":"2011","journal-title":"Lancet. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.critrevonc.2013.08.017","article-title":"Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer","volume":"89","author":"Colombo","year":"2014","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2902","DOI":"10.1200\/JCO.2007.12.1509","article-title":"Experience with bevacizumab in the management of epithelial ovarian cancer","volume":"25","author":"Burger","year":"2007","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"i40","DOI":"10.1093\/annonc\/mdw094","article-title":"PARP inhibitors in ovarian cancer","volume":"27","author":"Ledermann","year":"2016","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): A multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial","volume":"32","author":"Hilpert","year":"2014","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2217\/fon-2019-0042","article-title":"Bevacizumab use in the frontline, maintenance and recurrent settings for ovarian cancer","volume":"16","author":"Haunschild","year":"2020","journal-title":"Future Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.ygyno.2019.03.243","article-title":"Trends and characteristics of epithelial ovarian cancer in Japan between 2002 and 2015: A JSGO-JSOG joint study","volume":"153","author":"Machida","year":"2019","journal-title":"Gynecol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.ygyno.2010.02.021","article-title":"Bevacizumab toxicities and their management in ovarian cancer","volume":"117","author":"Randall","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ygyno.2007.01.038","article-title":"What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?","volume":"105","author":"Han","year":"2007","journal-title":"Gynecol. Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1200\/JCO.2013.53.6524","article-title":"Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study","volume":"32","author":"Burger","year":"2014","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S1470-2045(20)30637-9","article-title":"Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: A randomised, phase 3 trial","volume":"22","author":"Pignata","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1136\/ijgc-2019-000256","article-title":"Efficacy and safety results from GEICO 1205, a randomized phase II trial of neoadjuvant chemotherapy with or without bevacizumab for advanced epithelial ovarian cancer","volume":"29","author":"Mendiola","year":"2019","journal-title":"Int. J. Gynecol. Cancer Off. J. Int. Gynecol. Cancer Soc."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.ejca.2016.09.036","article-title":"Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA trial","volume":"70","author":"Rouzier","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/HYPERTENSIONAHA.117.10271","article-title":"Mechanisms of VEGF (Vascular Endothelial Growth Factor) Inhibitor-Associated Hypertension and Vascular Disease","volume":"71","author":"Pandey","year":"2018","journal-title":"Hypertension"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e006278","DOI":"10.1161\/JAHA.117.006278","article-title":"Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20,000 Patients","volume":"6","author":"Totzeck","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.22.01010","article-title":"Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST\/GINECO OV118\/ENGOT Ov-15 Open-Label Randomized Phase III Trial","volume":"41","author":"Pfisterer","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2147\/CMAR.S77400","article-title":"Cancer therapy and cardiovascular risk: Focus on bevacizumab","volume":"7","author":"Economopoulou","year":"2015","journal-title":"Cancer Manag. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1093\/annonc\/mdn713","article-title":"Management of hypertension in angiogenesis inhibitor-treated patients","volume":"20","author":"Izzedine","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Van Wynsberghe, M., Flejeo, J., Sakhi, H., Ollero, M., Sahali, D., Izzedine, H., and Henique, C. (2021). Nephrotoxicity of Anti-Angiogenic Therapies. Diagnostics, 11.","DOI":"10.3390\/diagnostics11040640"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF Inhibition and Renal Thrombotic Microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ygyno.2009.11.017","article-title":"Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma","volume":"116","author":"Diaz","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrclinonc.2009.94","article-title":"Adverse effects of anticancer agents that target the VEGF pathway","volume":"6","author":"Chen","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.ygyno.2009.10.069","article-title":"When \u2018never-events\u2019 occur despite adherence to clinical guidelines: The case of venous thromboembolism in clear cell cancer of the ovary compared with other epithelial histologic subtypes","volume":"116","author":"Duska","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Ngo, D.T.M., Williams, T., Horder, S., Kritharides, L., Vardy, J., Mandaliya, H., Nordman, I.I.C., Lynam, J., Bonaventura, T., and Sverdlov, A.L. (2020). Factors Associated with Adverse Cardiovascular Events in Cancer Patients Treated with Bevacizumab. J. Clin. Med., 9.","DOI":"10.3390\/jcm9082664"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"426","DOI":"10.3389\/fphar.2019.00426","article-title":"Bevacizumab Dose Affects the Severity of Adverse Events in Gynecologic Malignancies","volume":"10","author":"Lee","year":"2019","journal-title":"Front. Pharmacol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/5\/2065\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:48:49Z","timestamp":1760122129000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/5\/2065"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,6]]},"references-count":38,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["jcm12052065"],"URL":"https:\/\/doi.org\/10.3390\/jcm12052065","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2023,3,6]]}}}